Page 120 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 8 Pharmacogenomics and Hematologic Diseases 91

17. Ramsey LB, Panetta JC, Smith C, et al: Genome-wide study of metho- 24. Mullighan CG, Su X, Zhang J, et al: Deletion of IKZF1 and prognosis
trexate clearance replicates SLCO1B1. Blood 121(6):898–904, 2013. in acute lymphoblastic leukemia. New Engl J Med 360:470–480, 2009.
18. Ramsey LB, Bruun GH, Yang W, et al: Rare versus common variants in 25. Andersson AK, Ma J, Wang J, et al: The landscape of somatic mutations
pharmacogenetics: SLCO1B1 variation and methotrexate disposition. in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet
Genome Res 22:1–8, 2012. 47(4):330–337, 2015.
19. Zabriskie MS, Eide CA, Tantravahi SK, et al: BCR–ABL1 compound 26. Neff T, Armstrong SA: Recent progress toward epigenetic therapies: the
mutations combining key domain positions confer clinical resistance to example of mixed lineage leukemia. Blood 121(24):4847–4853, 2013.
ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26:428–442, 27. Annesley CE, Brown P: The biology and targeting of FLT3 in pediatric
2014. leukemia. Front Oncol 4:263, 2014. doi: 10.3389/fonc.2014.00263.
20. Luzzatto L, Seneca E: G6PD deficiency: a classic example of pharmacoge- eCollection 2014.
nomics with on-going clinical implications. Br J Haematol 164:469–480, 28. Roberts KG, Li Y, Payne-Turner D, et al: Targetable kinase-activating
2014. lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med
21. Relling MV, McDonagh EM, Chang T, et al: Clinical pharmacogenetics 371:1005–1015, 2014.
implementation consortium (CPIC) guidelines for rasburicase therapy 29. Hoffman JM, Haidar CE, Wilkinson MR, et al: PG4KDS: a model for
in the context of G6PD deficiency genotype. Clin Pharmacol Ther the pre-emptive implementation of pharmacogenetics. Am J Med Genet
96(2):169–174, 2014. C Semin Med Genet 166C:45–55, 2014.
22. Makarona K, Caputo VS, Costa JR, et al: Transcriptional and epigenetic 30. Ritchie MD, Holzinger ER, Li R, et al: Methods of integrating data
basis for restoration of G6PD enzymatic activity in human G6PD- to uncover genotype-phenotype interactions. Nat Rev Genet 16:85–97,
deficient cells. Blood 124(1):134–141, 2014. 2015.
23. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al: A subtype of 31. Relling MV, Evans WE: Pharmacogenomics in the clinic. Nature
childhood acute lymphoblastic leukemia with poor treatment outcome: 526:343–350, 2015.
a genome-wide classification study. Lancet Oncol 10:125–134, 2009.